Lannett Company, Inc. (NYSE:LCI) had its target price trimmed by Susquehanna from $50.00 to $41.00 in a research report report published on Wednesday morning, StockTargetPrices.com reports. The firm currently has a positive rating on the stock.

Lannett Company (NYSE:LCI) traded up 2.47% during trading on Wednesday, reaching $26.14. The company had a trading volume of 1,685,009 shares. The stock has a market cap of $954.82 million and a PE ratio of 6.55. Lannett Company has a 52-week low of $23.88 and a 52-week high of $72.44. The company has a 50-day moving average price of $36.48 and a 200 day moving average price of $44.95.

Lannett Company (NYSE:LCI) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.10. The firm had revenue of $106.40 million for the quarter, compared to analyst estimates of $103.90 million. The firm’s revenue for the quarter was up 14.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.94 earnings per share. On average, analysts anticipate that Lannett Company will post $3.76 earnings per share for the current year.

Other hedge funds have modified their holdings of the company. California State Teachers Retirement System boosted its stake in shares of Lannett Company by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 49,119 shares of the company’s stock valued at $1,971,000 after buying an additional 775 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in shares of Lannett Company by 2.5% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 38,730 shares of the company’s stock valued at $1,554,000 after buying an additional 936 shares during the period. Creative Planning boosted its stake in shares of Lannett Company by 24.2% in the fourth quarter. Creative Planning now owns 14,472 shares of the company’s stock valued at $581,000 after buying an additional 2,822 shares during the period. AT Bancorp boosted its stake in shares of Lannett Company by 46.6% in the fourth quarter. AT Bancorp now owns 56,624 shares of the company’s stock valued at $2,272,000 after buying an additional 17,989 shares during the period. Finally, Morgan Dempsey Capital Management LLC boosted its stake in shares of Lannett Company by 36.3% in the fourth quarter. Morgan Dempsey Capital Management LLC now owns 83,889 shares of the company’s stock valued at $3,366,000 after buying an additional 22,349 shares during the period.

LCI has been the topic of several other reports. Zacks Investment Research cut Lannett Company from a hold rating to a sell rating in a research report on Tuesday, November 24th. Oppenheimer reiterated a hold rating on shares of Lannett Company in a research report on Tuesday, December 29th. Craig Hallum lowered their price target on Lannett Company from $45.00 to $38.00 and set a hold rating on the stock in a research report on Wednesday, January 27th. Finally, Raymond James lowered their price target on Lannett Company to $45.00 in a research report on Wednesday, January 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $54.73.

Lannett Company, Inc. develops, manufactures, packages, markets and distributes solid oral (NYSE:LCI), extended release, topical and oral solution finished dosage forms of drugs. The Company also manufactures active pharmaceutical ingredients through its Cody Laboratories, Inc. (Cody Labs) subsidiary. The Company operates pharmaceutical manufacturing plants in Philadelphia, Pennsylvania and Cody, Wyoming. Customers of the Company’s pharmaceutical products include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, Governmental entities and health maintenance organizations. The Company’s products include Levothyroxine Sodium tablets, Digoxin tablets, Butalbital, Cocaine Topical Solution and Morphine Sulfate Oral Solution.

12 Month Chart for NYSE:LCI

Stock Target Prices

Receive News & Ratings for Lannett Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.